190 related articles for article (PubMed ID: 25623703)
1. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
Yamamoto S; Masuda H; Urakami S; Fujii Y; Sakamoto K; Kozuka T; Oguchi M; Fukui I; Yonese J
Urology; 2015 Feb; 85(2):407-13. PubMed ID: 25623703
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
3. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
[TBL] [Abstract][Full Text] [Related]
4. Bother problems in prostate cancer patients after curative treatment.
Stensvold A; Dahl AA; Brennhovd B; Småstuen MC; Fosså SD; Lilleby W; Steinsvik A; Axcrona K; Smeland S
Urol Oncol; 2013 Oct; 31(7):1067-78. PubMed ID: 22341412
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
6. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.
Lilleby W; Stensvold A; Dahl AA
Acta Oncol; 2014 Oct; 53(10):1380-9. PubMed ID: 24844918
[TBL] [Abstract][Full Text] [Related]
7. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
8. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Lubeck DP; Grossfeld GD; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes.
Mazzola CR; Deveci S; Heck M; Mulhall JP
BJU Int; 2012 Jul; 110(1):112-6. PubMed ID: 22093870
[TBL] [Abstract][Full Text] [Related]
10. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
11. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
13. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
Berge V; Thompson T; Blackman D
Scand J Urol Nephrol; 2007; 41(3):198-203. PubMed ID: 17469027
[TBL] [Abstract][Full Text] [Related]
14. Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses.
Abuodeh YA; Naghavi AO; Juan TH; Ma Z; Wilder RB
Int Braz J Urol; 2017; 43(4):628-637. PubMed ID: 28379660
[TBL] [Abstract][Full Text] [Related]
15. Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.
Omrcen T; Hrepic D; Boraska Jelavic T; Vrdoljak E
J BUON; 2015; 20(4):1061-7. PubMed ID: 26416057
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
Jayadevappa R; Chhatre S; Whittington R; Bloom BS; Wein AJ; Malkowicz SB
BJU Int; 2006 May; 97(5):955-62. PubMed ID: 16643477
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
19. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
